STOCK TITAN

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Vivos Therapeutics (NASDAQ: VVOS) reported third-quarter 2026 revenue of $6.4 million, with a narrower operating loss than a year earlier. Revenue rose 24% sequentially but fell from $6.8 million a year earlier. Operating loss narrowed 18% to $3.9 million as operating expenses fell 17%. Gross margin declined to 52% from 58%. Net loss narrowed to $2.0 million, including approximately $2.9 million of income from reversing an Employee Retention Credit liability.

Nine-month revenue rose to $16.7 million from $13.6 million, while operating loss widened to $15.3 million from $13.5 million. Cash was $247,000 at September 30, down from $2,029,000 at year-end. Vivos exchanged approximately $6.1 million of secured debt for equity during 2026. It completed the SOD Sciences transaction October 16 and regained Nasdaq equity compliance October 20, subject to continued monitoring. Vivos expects new clinical initiatives to contribute to revenue and margins beginning in Q4 2026.

Loading...
Loading translation...
16 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointSenior secured debt of approximately $6.1 million was exchanged for equity during 2026. 2.2× market cap
  • Major pointVivos estimates it has eliminated $5 million or more in annual operating costs, with further efficiencies underway.
  • Moderate pointThird-quarter revenue rose 24% sequentially to $6.4 million from $5.2 million.
  • Moderate pointThird-quarter operating loss narrowed 18% to $3.9 million from $4.7 million a year earlier.
  • Moderate pointThird-quarter net loss narrowed to $1.971 million from $5.400 million; approximately $2.9 million reflected a liability reversal. 1× market cap
  • Moderate pointNasdaq stockholders’ equity compliance was regained October 20, 2026.
10 minor points
  • Minor pointThird-quarter operating expenses fell 17% to $7.2 million from $8.7 million a year earlier.
  • Minor pointThird-quarter loss per share narrowed to $0.07 from $0.49 a year earlier.
  • Minor pointNine-month revenue increased to $16.708 million from $13.619 million a year earlier.
  • Minor pointService revenue rose 1% in Q3 to $4.6 million and 57% over nine months to $12.1 million.
  • Minor pointNine-month gross profit increased to $9.326 million from $7.554 million; gross margin rose to 56% from 55%.
  • Minor pointNine-month loss per share narrowed to $0.77 from $1.49 a year earlier.
  • Minor pointTotal liabilities declined to $20.693 million at September 30 from $26.702 million at December 31, 2025.
  • Minor pointStockholders’ equity reached $2.360 million at September 30, versus a $1.490 million deficit at year-end.
  • Minor pointSOD Sciences transaction completed October 16, 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Vivos expects clinical initiatives to contribute to revenue and margins beginning Q4 2026, increasingly throughout 2027.

Negative

  • Major pointCash fell to $247,000 at September 30, 2026, from $2,029,000 at December 31, 2025.
  • Major pointCurrent liabilities of $16.163 million exceeded current assets of $3.508 million at September 30, 2026.
  • Major pointCommon shares outstanding increased to 33,820,768 at September 30 from 9,286,609 at year-end, diluting existing holders.
  • Moderate pointThird-quarter revenue declined to $6.414 million from $6.783 million a year earlier.
  • Moderate pointThird-quarter gross profit fell to $3.314 million from $3.937 million; gross margin declined to 52% from 58%.
  • Moderate pointNine-month operating expenses increased to $24.662 million from $21.066 million, primarily reflecting Nevada center establishment costs.
  • Moderate pointNine-month operating loss widened to $15.336 million from $13.512 million a year earlier.
4 minor points
  • Minor pointProduct revenue declined to $1.772 million in Q3 and $4.567 million over nine months, versus $2.195 million and $5.893 million.
  • Minor pointNine-month net loss widened to $15.245 million from $14.276 million a year earlier.
  • Minor pointOther expense increased to $981,000 in Q3 and $3.199 million over nine months, versus $679,000 and $850,000.
  • Minor pointNasdaq equity compliance remains subject to continued monitoring.

News Explained

At September thirtieth, cash represented seven point two days of third-quarter operating cash outflow at that quarter’s rate.

At September 30, 2026, Vivos reported 33,820,768 common shares issued and outstanding, compared with 9,286,609 at December 31, 2025. The higher common-share count means existing holders’ percentage ownership was lower at quarter-end, absent offsetting changes.

Quarter-end cash of $247,000 equaled 7.2 days of third-quarter operating cash outflow at that quarter’s rate, a backward-looking comparison.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $247,000 / ($3,176,000 / 92) = 7.2 days

Key Figures

Q3 revenue: $6.4 million Nine-month revenue: $16.7 million Q3 operating loss: $3.9 million +5 more
Q3 revenue
$6.4 million
Q3 2026; up 24% from $5.2 million in Q2 2026
Nine-month revenue
$16.7 million
Nine months ended September 30, 2026; compared with $13.6 million in 2025
Q3 operating loss
$3.9 million
Q3 2026; improved 18% from $4.7 million in Q3 2025
Q3 net loss
$2.0 million
Q3 2026; compared with $5.4 million in Q3 2025
Cash and cash equivalents
$0.2 million
At September 30, 2026; compared with $2.0 million at December 31, 2025
Stockholders’ equity
$2.4 million
At September 30, 2026; compared with a $1.5 million deficit at December 31, 2025
Q3 gross margin
52%
Q3 2026; compared with 58% in Q3 2025
Total liabilities
$20.7 million
At September 30, 2026; down from $26.7 million at December 31, 2025

Previous Earnings Reports

2 past events · Latest: Aug 14
Same Type 2 events
  1. Aug 14

    Q2 earnings

    24h Move
    -12.3%

    Q2 revenue grew 35% year over year, with a $5.5 million net loss.

  2. May 20

    Q1 earnings

    24h Move
    -0.9%

    Revenue rose 70% year over year, while net loss widened to $7.8 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

osa, cpap, eeg, 510(k) clearance, +1 more
5 terms
osa medical
"obstructive sleep apnea (“OSA”)"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
cpap medical
"distribution and set-up of PAP and CPAP treatments"
A CPAP (continuous positive airway pressure) device is a machine that gently blows a steady stream of air through a mask to keep a person’s breathing passages open during sleep, commonly used to treat sleep apnea. For investors, CPAPs matter because they represent a medical-device market with recurring sales of equipment and disposable supplies, subject to safety reviews, insurance reimbursement rules and regulatory approvals that can affect a maker’s revenue and reputation.
eeg medical
"including EEG testing and treatment for insomnia"
An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.
510(k) clearance regulatory
"FDA 510(k) clearance for treating severe OSA in adults"
A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.
form 10-q regulatory
"Quarterly Report on Form 10-Q for the three and nine months"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders’ equity requirement

Management to Host Conference Call today at 5:00 pm ET

LITTLETON, Colo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and nine months ended September 30, 2026.

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway. We also exchanged approximately $6.1 million of senior secured debt for equity during 2026 and, following the closing of our SOD Sciences transaction in October, regained compliance with Nasdaq’s stockholders’ equity requirement.”

Mr. Huntsman continued, “We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”

Third Quarter 2026 Financial and Operating Summary

  • Revenue was $6.4 million for the third quarter of 2026, up 24% from $5.2 million in the second quarter of 2026, and $16.7 million for the nine months ended September 30, 2026, compared to $6.8 million and $13.6 million for the three and nine months ended September 30, 2025. Third quarter service revenue increased 1% to $4.6 million, while product revenue decreased to $1.8 million from $2.2 million, reflecting our strategic pivot away from appliance sales to dentists in our Vivos Integrated Provider (VIP) program. For the nine months, service revenue increased 57% to $12.1 million, primarily attributable to sleep testing and resulting treatment services in our Nevada operations;

  • Gross profit was $3.3 million for the third quarter of 2026 and $9.3 million for the nine months ended September 30, 2026, compared to $3.9 million and $7.6 million for the comparable periods in 2025. The third quarter decrease was due to lower product revenue and higher cost of sales, while the nine-month increase was due to stronger service revenue;

  • Gross margin was 52% in the third quarter of 2026 compared to 58% in the third quarter of 2025, due to the decrease in product revenue. For the nine months ended September 30, 2026, gross margin was 56% compared to 55% in the same period in 2025;

  • Operating expenses for the third quarter ended September 30, 2026 were $7.2 million, a 17% decrease compared to $8.7 million in the same period a year ago, reflecting a $1.4 million reduction in general and administrative expenses, driven primarily by lower professional fees, equipment maintenance and office expenses, as well as lower sales and marketing expenses. For the nine months ended September 30, 2026, operating expenses were $24.7 million versus $21.1 million in the same period in 2025, an increase driven primarily by the costs of establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada;

  • The third quarter 2026 operating loss improved 18% to $3.9 million, compared to $4.7 million in the third quarter of 2025. For the nine months ended September 30, 2026, the operating loss was $15.3 million compared to $13.5 million for the nine months ended September 30, 2025.

  • Net loss for the third quarter of 2026 was $2.0 million, compared to $5.4 million in the third quarter of 2025, and included approximately $2.9 million of other income from the reversal of our previously recorded Employee Retention Credit liability;

  • At September 30, 2026, cash and cash equivalents were $0.2 million and total stockholders’ equity was $2.4 million, compared to cash and cash equivalents of $2.0 million and a stockholders’ deficit of $1.5 million as of December 31, 2025. Total liabilities decreased to $20.7 million at September 30, 2026 from $26.7 million at December 31, 2025. Subsequent to quarter end, on October 16, 2026, we completed our SOD Sciences transaction, and on October 20, 2026, Nasdaq notified us that we had regained compliance with its minimum stockholders’ equity requirement, subject to Nasdaq’s continued monitoring.

Investor Call and 10-Q Filing

Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic initiatives and their anticipated effect on near-term revenue growth and cash burn.

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The Access ID for the replay is 1177865.  The replay will be available until Monday, November 30, 2026.  

A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available at Vivos’ website for 30 days following the call.

In addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional information about Vivos’ financial performance is provided in Vivos’ Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026, which has been filed with the Securities and Exchange Commission (“SEC”). This press release discusses certain financial information for the second quarter ended June 30, 2026, and more information about our results for the second quarter are included in Vivos’ Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, which has been filed with the SEC.  The full 10-Q reports will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17.  Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices were the first oral appliances to receive FDA 510(k) clearance for treating severe OSA in adults and the flagship DNA appliance is the first oral appliance to receive FDA clearance for treating moderate to severe OSA in children. 

OSA and insomnia affect over 1 billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue - they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood.  As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices target the underlying physiology and anatomical deficiencies that are often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward‑Looking Statements

This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”, “will”, “would”, “could”, “potential”, “continue” and variations of such words and similar expressions are intended to identify forward-looking statements.

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual benefits of the cost reductions, clinical initiatives and other matters described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, its ability to meet Nasdaq’s stockholders’ equity and minimum bid price requirements; (v) the risk that Vivos will not have enough cash to fund its operations and continue as a going concern; (vi) the risk that the final accounting for the SOD Sciences transaction, or review by Nasdaq or Vivos’ independent registered public accounting firm, results in a smaller increase in stockholders’ equity than expected; (vii) the risk that Vivos will not regain compliance with Nasdaq’s minimum bid price requirement by December 2, 2026 or any extended deadline, or that stockholders will not approve the proposed reverse stock split, or that the closing bid price of Vivos’ common stock will be $0.10 or less for ten consecutive business days, which would result in a Nasdaq delisting determination and suspension of trading without any compliance period; (viii) the risk that the cost reductions described in this press release will not produce the expected savings; (ix) the risk that Vivos’ new clinical initiatives and payer contract renegotiations will not increase revenue or margins when expected, or at all, including because of reimbursement, licensing or other regulatory requirements; (x) dilution from the conversion of outstanding preferred stock; (xi) market and other conditions; and (xii) the other risk factors described in Vivos’ filings with the SEC, including under “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Vivos’ filings can be obtained free of charge on the SEC’s website at  www.sec.gov.

Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

-Financial Tables Follow-

VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
            
 Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
 2026  2025  2026  2025 
Revenue               
Product revenue$1,772  $2,195  $4,567  $5,893 
Service revenue 4,642   4,588   12,141   7,726 
Total revenue 6,414   6,783   16,708   13,619 
                
Cost of sales (exclusive of depreciation and amortization shown separately below) 3,100   2,846   7,382   6,065 
                
Gross profit 3,314   3,937   9,326   7,554 
                
Operating expenses               
General and administrative 6,450   7,884   22,533   19,181 
Sales and marketing 210   403   614   1,018 
Depreciation and amortization 550   384   1,515   867 
                
Total operating expenses 7,210   8,671   24,662   21,066 
                
Operating loss (3,896)  (4,734)  (15,336)  (13,512)
                
Non-operating income (expense)               
Other expense (981)  (679)  (3,199)  (850)
Other income 2,906   13   3,290   86 
Loss before income taxes (1,971)  (5,400)  (15,245)  (14,276)
                
Net loss$(1,971) $(5,400) $(15,245) $(14,276)
Net loss attributable to non-controlling interest (26)  -   (137)  - 
Net loss attributable to stockholders$(1,945) $(5,400) $(15,108) $(14,276)
Net loss per share (basic and diluted)$(0.07) $(0.49) $(0.77) $(1.49)
Weighted average number of shares of Common Stock outstanding (basic and diluted) 26,528,253   10,963,590   19,658,339   9,557,368 
                

See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

VIVOS THERAPEUTICS INC.
Unaudited Condensed Consolidated Balance Sheets
(In Thousands, Except Per Share Amounts)
 
 September 30,
2026
  December 31,
2025
 
Current assets       
Cash and cash equivalents$247  $2,029 
Accounts receivable, net of allowance of $1,250 and $882, respectively 2,370   1,581 
Prepaid expenses and other current assets 891   774 
        
Total current assets 3,508   4,384 
        
Long-term assets       
Goodwill 8,572   8,572 
Property and equipment, net 3,347   3,757 
Operating lease right-of-use asset 3,624   4,166 
Intangible assets, net 3,438   4,045 
Deposits and other 367   228 
        
Total assets$22,856  $25,152 
        
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)       
Current liabilities       
Accounts payable$2,739  $1,679 
Accrued expenses 8,819   5,988 
Contract liabilities 72   479 
Current portion of operating lease liability 850   672 
Current portion of financing lease liability 57   55 
Current portion of debt 1,502   8,353 
Other current liabilities 2,124   850 
        
Total current liabilities 16,163   18,076 
        
Long-term liabilities       
Employee retention credit liability -   2,904 
Operating lease liability, net of current portion 3,198   3,840 
Financing lease liability, net of current portion 69   113 
Debt, net of current portion 313   469 
Other liabilities 950   1,300 
        
Total liabilities 20,693   26,702 
        
Commitments and contingencies -   - 
        
Stockholders’ equity/(deficit)       
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; 3,610,995 shares issued and outstanding$-  $- 
Preferred Stock – additional paid in capital 3,605   - 
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 33,820,768 shares as of September 30, 2026 and 9,286,609 shares as of December 31, 2025 3   1 
Additional paid-in capital 139,217   123,866 
Accumulated deficit (140,465)  (125,357)
Total stockholders’ equity/(deficit) 2,360   (1,490)
        
Non-controlling interest (197)  (60 
Total equity/(deficit) 2,163   (1,550)
        
Total liabilities and equity/(deficit)$22,856  $25,152 
        

See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Vivos Therapeutics’ third-quarter 2026 financial results?

Vivos reported $6.4 million in revenue, a $3.9 million operating loss and a $2.0 million net loss. Revenue rose 24% from the second quarter but declined from $6.8 million a year earlier. Net loss included approximately $2.9 million of other income from reversing an Employee Retention Credit liability.

Did VVOS regain compliance with Nasdaq’s stockholders’ equity requirement?

Nasdaq notified Vivos on October 20, 2026, that it had regained compliance with the minimum stockholders’ equity requirement, subject to continued monitoring. The notification followed completion of the SOD Sciences transaction on October 16, 2026.

What clinical initiatives is Vivos pursuing to improve revenue and margins?

Vivos is pursuing EEG testing and treatment for insomnia and other non-OSA sleep disorders, PAP and CPAP treatment distribution and setup, and remote monitoring of CPAP users at its SCN and SAMC centers, alongside payer-contract renegotiations. The company expects contributions to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.

Keep reading